







ORGANISM	STD	3	4	4a	4b
STAPHYLOCOCCUS AUREUS (ATCC 9144)	32 mm	17 mm	19 mm	22 mm	20 mm
STAPHYLOCOCCUS EPIDERMIDIS (ATCC 155)	29 mm	15 mm	17 mm	20 mm	22 mm
ESCHERICHIA COLI (ATCC 25922)	31 mm	14 mm	17 mm	22 mm	23 mm
KLEBSIELLA PNEUMONIAE (ATCC 11298)	28 mm	13 mm	15 mm	18 mm	19 mm
CANDIDA ALBICANS (ATCC 9029)	29 mm	17 mm	19 mm	25 mm	23 mm

### 3. Conclusion

In recent study of four compounds of Nicotinamide-Oxazole derivatives was subjected to antibacterial and antifungal bio-assay. All four compounds were bio-active and it was concluded that all the prepared compounds were found to possess the significant activity with low toxicity. Further synthesis of new nicotinamide-oxazole derivatives and biological studies can be done as the present results encouraged to the limit where it can be future new antimicrobial agents.

### Acknowledgement:

Both the authors wants to thanks Management of B S Abdur Rahman Crescent institute of science and technology management for wonderful facilities offered. HV wants to thank MIT Dean, HOD of Chemistry for suggestions, rendering help.

### Reference

- [1] A.K.Ghose, V.N.Viswanadhan, J.J.Wendoloski, "A Qualitative and Quantitative Characterization of Known Drug Databases", J.Comb.Chem, 1999, 1, 55-68.
- [2] Pierre Kyme, Nils H.Thoennissen, Ching Wen Tseng, Gabriel B.Thoennissen, Andrea J.Wolf, Kenichi shimada, Utz O.Krug, Kunik Lee, Carsten Muller-Tidow, Wolfgang E.Berdel, W.David, Hardy, Adrian F.Gombart, EBR mediates nicotinamide-enhanced clearance of Staphylococcus aureus in mice. Journal of clinical investigation, 2012, DOI: 10.1172/JCI62070
- [3] G.L. Patrick, An Introduction to Medical Chemistry-Second Edition (2001), Oxford University Press, Oxford.
- [4] Christian Montalbetti and Virginie Falque, "Amide bond formation and peptide coupling", Tetrahedron, 2005, 61, 10827-10852.
- [5] Michael F.Murray, "Nicotinamide: An Oral Antimicrobial Agent with Activity against Both Mycobacterium tuberculosis and Human Immunodeficiency Virus", Nicotinamide Therapy, Clinical infectious diseases, 2003, 36, 453-460.
- [6] M.Fukuzawa et al, "Inhibitory effect of nicotinamide on in vitro and invivo production of tumor necrosis factor", Immunology letters, 1997, 59, 1, 7-11.
- [7] Kushner et al, "Experimental Chemotherapy of Tuberculosis.I.substituted nicotinamides", Journal of Organic Chemistry, 1948, 13, 6, 834-836.




Fig (1) shows Proton NMR spectrum of Compound 5




Fig (2) shows Proton NMR spectrum of Compound 6